Pharmaids Pharmaceuticals (524572) Q2 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2024 were approved and reviewed by the Board and Audit Committee.

• Independent auditors issued unmodified review reports for both standalone and consolidated results.

Financial highlights

• Standalone revenue from operations for Q2 FY25 was ₹83.40 lakhs, with a net loss of ₹100.66 lakhs; for H1 FY25, revenue was ₹166.65 lakhs and net loss ₹263.00 lakhs.

• Consolidated revenue from operations for Q2 FY25 was ₹523.93 lakhs, with a net loss of ₹256.31 lakhs; for H1 FY25, revenue was ₹997.00 lakhs and net loss ₹568.76 lakhs.

• Basic and diluted EPS (standalone) for Q2 FY25 was ₹(0.29); for H1 FY25, ₹(0.75).

• Basic and diluted EPS (consolidated) for H1 FY25 was negative, reflecting continued losses.

Outlook and guidance

• The group continues to operate in the Contract Research and Manufacturing Services segment.